ALNY Alnylam Pharmaceuticals Inc

Price (delayed)

$182.41

Market cap

$21.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.54

Enterprise value

$21.58B

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is ...

Highlights
The company's revenue has surged by 100% YoY and by 16% QoQ
The gross profit has soared by 89% YoY and by 15% from the previous quarter
The company's quick ratio fell by 12% YoY but it rose by 9% QoQ
The debt has soared by 70% YoY
The equity has contracted by 31% YoY and by 9% from the previous quarter

Key stats

What are the main financial stats of ALNY
Market
Shares outstanding
117.55M
Market cap
$21.44B
Enterprise value
$21.58B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
23.04
Price to sales (P/S)
37.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
37.8
Earnings
Revenue
$570.94M
EBIT
-$756.22M
EBITDA
-$675.93M
Free cash flow
-$672.38M
Per share
EPS
-$7.54
Free cash flow per share
-$5.74
Book value per share
$7.92
Revenue per share
$4.88
TBVPS
$27.8
Balance sheet
Total assets
$3.26B
Total liabilities
$2.33B
Debt
$518.52M
Equity
$926.19M
Working capital
$1.98B
Liquidity
Debt to equity
0.56
Current ratio
4.99
Quick ratio
3.68
Net debt/EBITDA
-0.21
Margins
EBITDA margin
-118.4%
Gross margin
83.2%
Net margin
-153.5%
Operating margin
-140.9%
Efficiency
Return on assets
-26.3%
Return on equity
-76.9%
Return on invested capital
-27.2%
Return on capital employed
-27.4%
Return on sales
-132.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALNY stock price

How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
0.33%
1 week
2.74%
1 month
4.46%
1 year
17.98%
YTD
40.35%
QTD
7.6%

Financial performance

How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$570.94M
Gross profit
$475.13M
Operating income
-$804.53M
Net income
-$876.35M
Gross margin
83.2%
Net margin
-153.5%
The company's revenue has surged by 100% YoY and by 16% QoQ
The gross profit has soared by 89% YoY and by 15% from the previous quarter
The company's operating margin has surged by 58% YoY and by 16% QoQ
The net margin has soared by 50% YoY and by 12% from the previous quarter

Growth

What is Alnylam Pharmaceuticals's growth rate over time

Valuation

What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
23.04
P/S
37.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
37.8
ALNY's EPS is up by 6% year-on-year
ALNY's price to book (P/B) is 180% more than its 5-year quarterly average of 8.2 and 56% more than its last 4 quarters average of 14.7
The equity has contracted by 31% YoY and by 9% from the previous quarter
The company's revenue has surged by 100% YoY and by 16% QoQ
ALNY's price to sales (P/S) is 56% lower than its 5-year quarterly average of 84.1

Efficiency

How efficient is Alnylam Pharmaceuticals business performance
ALNY's return on sales has surged by 57% year-on-year and by 15% since the previous quarter
ALNY's return on invested capital is up by 48% year-on-year and by 12% since the previous quarter
The ROE has contracted by 34% YoY and by 12% from the previous quarter
The return on assets has increased by 26% year-on-year and by 5% since the previous quarter

Dividends

What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNY.

Financial health

How did Alnylam Pharmaceuticals financials performed over time
The total assets is 40% more than the total liabilities
The company's total liabilities has surged by 150% YoY but it fell by 2.6% QoQ
The total assets has increased by 43% YoY but it has decreased by 4.5% from the previous quarter
The debt is 44% less than the equity
Alnylam Pharmaceuticals's debt to equity has soared by 143% YoY and by 10% from the previous quarter
The debt has soared by 70% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.